Validation of a prion and virus purification process in the manufacture of bovine thrombin

Journal of Applied Research

Volumn 7, Issue 3, 2007, Pages 217-226

  Terrab, Abdel ^a   Pawlak, Dan ^a  

^a King Pharmaceuticals   (United States)

Author keywords

Bovine thrombin; Manufacture; Prions; Transmission; Virus

Indexed keywords

THROMBIN;

ANIMAL CELL; ARTICLE; BOVINE DIARRHEA VIRUS; BRAIN HOMOGENATE; CELL ASSAY; CONTROLLED STUDY; DRUG MANUFACTURE; HAMSTER; MEMBRANE FILTER; MOLECULAR MODEL; MURINE LEUKEMIA VIRUS; NONHUMAN; PARVOVIRUS; PRION DISEASE; PSEUDORABIES HERPETOVIRUS; SCRAPIE AGENT; VALIDATION PROCESS; VIRUS INFECTIVITY; VIRUS LOAD; VIRUS PURIFICATION; VIRUS TITRATION; VIRUS TRANSMISSION; WESTERN BLOTTING;

EID: 36148945958     PISSN: 1537064X     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (19)

1. Lawson JH. The clinical use and immunologic impact of thrombin in surgery. Semin Thromb Hemost. 2006;32:98-100.
2. Lundblad RL, Bradshaw RA, Gabriel D, et al. A review of the therapeutic uses of thrombin. Thromb Haemost. 2004;91:851-860.
3. Oz M, Rondinone JF, Shargill NS. Floseal Matrix: new generation topical hemostatic sealant. J Card Surg. 2003;18:486-493.
4. Beer MH, Berkow R, eds. The Merck Manual of Diagnosis and Therapy. 18th ed. Sec. 11, Ch. 131: Acquired coagulation disorders. West Point, PA: Merck & Co, Inc.; 2006.
5. Bishop PD, Lewis KB, Schultz J, et al. Comparison of recombinant human thrombin and plasma-derived human alpha-thrombin. Semin Thromb Hemost. 2006;32(suppl 1):96-97.
6. Yonemura H, Imamura T, Soejima K, et al. Preparation of recombinant alpha-thrombin: high-level expression of recombinant human prethrombin-2 and its activation by recombinant ecarin. J Biochem (Tokyo). 2004;135:577-582.
7. Gabay M. Absorbable hemostatic agents. Am J Health Syst Pharm. 2006;63:1244-1253.
8. Burdick MD, Pifat DY, Petteway SR Jr, et al. Clearance of prions during plasma protein manufacture. Trans Med Rev. 2006;20:57-62.
9. Cai K, Gierman TM, Hotta J, et al. Ensuring the biologic safety of plasma-derived therapeutic proteins. BioDrugs. 2005;19:79-96.
10. Prusiner SB. Prions. Proc Natl Acad Sci USA. 1998;95:13363-13383.
11. European Agency for the Evaluation of Medicinal Products. Committee for Proprietary Medicinal Products. Note for guidance on virus validation studies: the design, contribution and interpretation of studies validating the inactivation and removal of viruses. 14 February 1996. Available at: http://www.emea.eu.int/pdf/human/bwp/026895en.pdf. Accessed November 3, 2006.
12. Burnouf T, Radosevich M. Nanofiltration of plasma-derived biopharmaceutical products. Haemophilia. 2003;9:24-37.
13. Liao YC, Lebo RV, Clawson GA, et al. Human prion protein cDNA: molecular cloning, chromosomal mapping, and biological implications. Science. 1986;233:364-367.
14. Bendheim PE, Bockman JM, McKinley MP. Scrapie and CJD prion protein share physical properties and antigenic determinants. Proc Natl Acad Sci USA. 1985;82:997-1001.
15. McKinley MP, Bolton DC, Prusiner SB. A protease-resistant protein is a structural component of the scrapie prion. Cell. 1983;35:57-62.
16. Data on file. King Pharmaceuticals, Inc.
17. Lee DC, Stenland CJ, Hartwell RC, et al. Monitoring plasma processing steps with a sensitive Western blot assay for the detection of the prion protein. J Virol Methods. 2000;84:77-89.
18. Data on file. Pall Filtron, Corp.
19. Lee DC, Stenland CJ, Miller JL, et al. A direct relationship between the partitioning of the pathogenic prion protein and transmissible spongiform encephalopathy infectivity during the purification of plasma proteins. Transfusion. 2001;41:449-455.